Article Data

  • Views 475
  • Dowloads 145

Original Research

Open Access

The top 100 most cited manuscripts in breast-conserving surgery for breast cancer: a bibliometric analysis

  • Yang Li1,2
  • Pingming Fan3
  • Xu-Chen Cao1,*,†,
  • Peng-fei Lyu1,3,*,†,

1The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, 300060 Tianjin, China

2Department of Breast Surgery, Inner Mongolia Forestry General Hospital (Inner Mongolian Nationality Second College of Clinical Medicine), 022150 Hulun Buir, Inner Mongolia, China

3Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, 570102 Haikou, Hainan, China

DOI: 10.22514/ejgo.2024.032 Vol.45,Issue 2,April 2024 pp.100-111

Submitted: 22 January 2023 Accepted: 14 March 2023

Published: 15 April 2024

*Corresponding Author(s): Xu-Chen Cao E-mail:
*Corresponding Author(s): Peng-fei Lyu E-mail:

† These authors contributed equally.


Breast conserving surgery (BCS) for breast cancer is widely performed. This study aimed to identify the characteristics of the 100 most cited articles in BCS research. The 100 most cited articles were retrieved from the Web of Science datasbase. Using bibliometric tools, the contributions of countries, institutions, authors, and of research development were analyzed. The country with the highest number of manuscripts in the top 100 was the United States (n = 59). The Memorial Sloan Kettering Cancer Center and University of Pennsylvania each published 21 articles. Bartelink H, Harris JR, and Morrow M each published eight articles. Among the top 100 most cited articles, hotspots focused on breast-conserving margins, recurrence, distant metastases, radiotherapy, and some controlled trials. Surgical margin, recurrence, distant metastases, radiation therapy are the hot topics in these 100 articles. There may be new radiotherapy modalities to improve the efficacy of post-operative radiotherapy in the future. The results of this review provide breast surgeons with research highlights and hot spots in the field of BCS and predict the future.


Breast-conserving surgery; Top 100; Top-cited; Bibliometric; Visualized study

Cite and Share

Yang Li,Pingming Fan,Xu-Chen Cao,Peng-fei Lyu. The top 100 most cited manuscripts in breast-conserving surgery for breast cancer: a bibliometric analysis. European Journal of Gynaecological Oncology. 2024. 45(2);100-111.


[1] NewsCAP: Breast cancer is now the most diagnosed cancer worldwide. American Journal of Nursing. 2021; 121: 15.

[2] Gadaleta E, Thorn GJ, Ross-Adams H, Jones LJ, Chelala C. Field cancerization in breast cancer. The Journal of Pathology. 2022; 257: 561–574.

[3] Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. The Lancet. 2021; 397: 1750–1769.

[4] Qian C, Liang Y, Yang M, Bao SN, Bai JL, Yin YM, et al. Effect of breast-conserving surgery plus radiotherapy versus mastectomy on breast cancer-specific survival for early-stage contralateral breast cancer. Gland Surgery. 2021; 10: 2978–2996.

[5] Apantaku LM. Breast-conserving surgery for breast cancer. American Family Physician. 2002; 66: 2271–2278.

[6] Whelan TJ, Lada BM, Laukkanen E, Perera FE, Shelley WE, Levine MN, et al. Breast radiotherapy after breast-conserving surgery. Canadian Medical Association. Journal. 1998; 158: S35–S42.

[7] De Lorenzi F, Loschi P, Bagnardi V, Rotmensz N, Hubner G, Mazzarol G, et al. Oncoplastic breast-conserving surgery for tumors larger than 2 centimeters: is it oncologically safe? A matched-cohort analysis. Annals of Surgical Oncology. 2016; 23: 1852–1859.

[8] Kostiuchenko Y, Motuzyuk I, Sydorchuk O, Kovtun N, Krotevich M. Safe resection margins in breast-conserving surgery. Annals of Oncology. 2017; 28: v69.

[9] Zhang MD, Wu KJ, Zhang P, Wang ML, Bai F, Chen HL. Breast-conserving surgery is oncologically safe for well-selected, centrally located breast cancer. Annals of Surgical Oncology. 2021; 28: 330–339.

[10] Acea-Nebril B, García-Novoa A, Cereijo-Garea C, Builes-Ramirez S, Bouzon-Alejandro A, Mosquera-Oses J. Single-incision approach for breast-conserving surgery: effectiveness, complications and quality of life. Annals of Surgical Oncology. 2019; 26: 2466–2474.

[11] Acil H, Cavdar I. Comparison of quality of life of Turkish breast cancer patients receiving breast conserving surgery or modified radical mastectomy. Asian Pacific Journal of Cancer Prevention. 2014; 15: 5377–5381.

[12] Aristokleous I, Saddiq M. Quality of life after oncoplastic breast-conserving surgery: a systematic review. ANZ Journal of Surgery. 2019; 89: 639–646.

[13] Zafrakas M, Eskitzis P, Demetriades I, Sympilidis G, Panagopoulou E, Papanikolaou A, et al. Quality of life in breast cancer patients undergoing breast conserving surgery in Greece. European Breast Cancer Conference. 2014; 50: S93.

[14] Wallin JA. Bibliometric methods: pitfalls and possibilities. Basic & Clinical Pharmacology & Toxicology. 2005; 97: 261–275.

[15] Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: how great is the impact? Scientometrics. 2015; 105: 1809–1831.

[16] Maz-Machado A, Torralbo-Rodriguez M, Vallejo-Ruiz M, Bracho-López R. Bibliometric analysis of scholarly production from the university of Malaga in the social sciences citation index (1998–2007). Revista Española de Documentación Científica. 2010; 33: 582–599. (In Spanish)

[17] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. The Lancet. 2011; 378: 1707–1716.

[18] Malmström P, Holmberg L, Anderson H, Mattsson J, Jönsson PE, Tennvall-Nittby L, et al.; Swedisj Breast Cancer Group. Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. European Journal of Cancer. 2003; 39: 1690–1697.

[19] Jagsi R, Li Y, Morrow M, Janz N, Alderman A, Graff J, et al. Patient-reported quality of life and satisfaction with cosmetic outcomes after breast conservation and mastectomy with and without reconstruction: results of a survey of breast cancer survivors. Annals of Surgery. 2015; 261: 1198–1206.

[20] Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. The New England Journal of Medicine. 2002; 347: 1233–1241.

[21] Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. The New England Journal of Medicine. 2002; 347: 1227–1232.

[22] Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of surgical oncology—American society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Journal of Clinical Oncology. 2014; 32: 1507–1515.

[23] Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond MEH, Lyman GH, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American society of clinical oncology endorsement of the society of surgical oncology/American society for radiation oncology consensus guideline. Journal of Clinical Oncology. 2014; 32: 1502–1506.

[24] Pleijhuis RG, Graafland M, de Vries J, Bart J, de Jong JS, van Dam GM. Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Annals of Surgical Oncology. 2009; 16: 2717–2730.

[25] Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. Journal of Clinical Oncology. 2000; 18: 1668–1675.

[26] Leong C, Boyages J, Jayasinghe UW, Bilous M, Ung O, Chua B, et al. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma. Cancer. 2004; 100: 1823–1832.

[27] Houssami N, Macaskill P, Luke Marinovich M, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Annals of Surgical Oncology. 2014; 21: 717–730.

[28] Tyler S, Truong PT, Lesperance M, Nichol A, Baliski C, Warburton R, et al. Close margins less than 2 mm are not associated with higher risks of 10-year local recurrence and breast cancer mortality compared with negative margins in women treated with breast-conserving therapy. International Journal of Radiation Oncology, Biology, Physics. 2018; 101: 661–670.

[29] Lin J, Lin K, Wang Y, Huang L, Chen SL, Chen D. Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy. BMC Cancer. 2020; 20: 451.

[30] Wimmer K, Bolliger M, Bago-Horvath Z, Steger G, Kauer-Dorner D, Helfgott R, et al. Impact of surgical margins in breast cancer after preoperative systemic chemotherapy on local recurrence and survival. Annals of Surgical Oncology. 2020; 27: 1700–1707.

[31] Cendan JC, Coco D, Copeland EM. Accuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed margins. Journal of the American College of Surgeons. 2005; 201: 194–198.

[32] Kho E, de Boer LL, Van de Vijver KK, van Duijnhoven F, Vrancken Peeters MTFD, Sterenborg HJCM, et al. Hyperspectral imaging for resection margin assessment during cancer surgery. Clinical Cancer Research. 2019; 25: 3572–3580.

[33] Partain N, Calvo C, Mokdad A, Colton A, Pouns K, Clifford E, et al. Differences in re-excision rates for breast-conserving surgery using intraoperative 2D versus 3D tomosynthesis specimen radiograph. Annals of Surgical Oncology. 2020; 27: 4767–4776.

[34] Hwang ES, Beitsch P, Blumencranz P, Carr D, Chagpar A, Clark L, et al. Clinical impact of intraoperative margin assessment in breast-conserving surgery with a novel pegulicianine fluorescence-guided system: a nonrandomized controlled trial. JAMA Surgery. 2022; 157: 573-580.

[35] Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. Journal of Clinical Oncology. 2008; 26: 2373–2378.

[36] Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. Journal of Clinical Oncology. 2011; 29: 2852–2858.

[37] Freedman GM, Anderson PR, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009; 115: 946–951.

[38] Tartter PI, Kaplan J, Bleiweiss I, Gajdos C, Kong A, Ahmed S, et al. Lumpectomy margins, reexcision, and local recurrence of breast cancer. The American Journal of Surgery. 2000; 179: 81–85.

[39] Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordiere A, Vincent-Salomon A, et al. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiotherapy and Oncology. 2007; 82: 272–280.

[40] Wang LZ, He YJ, Li JF, Wang TF, Xie YT, Fan ZQ, et al. Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method. Breast Cancer Research and Treatment. 2020; 183: 717–728.

[41] Li P, Li L, Xiu B, Zhang L, Yang B, Chi Y, et al. The prognoses of young women with breast cancer (≤35 years) with different surgical options: a propensity score matching retrospective cohort study. Frontiers in Oncology. 2022; 12: 795023.

[42] Voogd AC, van Tienhoven G, Peterse HL, Crommelin MA, Rutgers EJT, van de Velde CJ, et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch study group on local recurrence after breast conservation (BORST). Cancer. 1999; 85: 437–446.

[43] Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, et al. Ipsilateral breast tumor recurrence (Ibtr) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer. 2006; 106: 35–41.

[44] Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK import low trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet. 2017; 390: 1048–1060.

[45] van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. The Lancet. Oncology. 2016; 17: 1158–1170.

[46] Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. The Lancet. Oncology. 2015; 16: 47–56.

[47] Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Annals of Oncology. 2001; 12: 997–1003.

[48] Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. The Lancet. Oncology. 2015; 16: 266–273.

[49] Arthur DW, Winter K, Kuske RR, Bolton J, Rabinovitch R, White J, et al. A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. International Journal of Radiation Oncology, Biology, Physics. 2008; 72: 467–473.

[50] Offersen BV, Overgaard M, Kroman N, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiotherapy and Oncology. 2009; 90: 1–13.

[51] André C, Holsti C, Svenner A, Sackey H, Oikonomou I, Appelgren M, et al. Recurrence and survival after standard versus oncoplastic breast-conserving surgery for breast cancer. BJS Open. 2021; 5: zraa013.

[52] Fitzal F, Bolliger M, Dunkler D, Geroldinger A, Gambone L, Heil J, et al. Retrospective, multicenter analysis comparing conventional with oncoplastic breast conserving surgery: oncological and surgical outcomes in women with high-risk breast cancer from the OPBC-01/iTOP2 study. Annals of Surgical Oncology. 2022; 29: 1061–1070.

[53] Matar R, Sevilimedu V, Gemignani ML, Morrow M. Impact of endocrine therapy adherence on outcomes in elderly women with early-stage breast cancer undergoing lumpectomy without radiotherapy. Annals of Surgical Oncology. 2022; 29: 4753–4760.

[54] Rocco N, Catanuto G, Cinquini M, Audretsch W, Benson J, Criscitiello C, et al. Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations. Breast. 2021; 57: 25–35.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time